Continual and partial MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish
Open Access
- 1 January 2012
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 5 (4), 546-552
- https://doi.org/10.1242/dmm.008672
Abstract
Summary: Cardio-facio-cutaneous (CFC) syndrome is caused by germ-line mutations in RAS, BRAF and MEK. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a one-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK dependent tissues. We now test 10 different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development, and craniofacial structures in zebrafish embryos. Notably, we find that a continuous, partial dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAFQ257R kinase-active allele and the BRAFG596V kinase-impaired mutant allele through the first five days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer that requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK activity treatment is sufficient to moderate the developmental effects BRAFCFC mutations.This publication has 29 references indexed in Scilit:
- The Phosphatase SHP2 Regulates the Spacing Effect for Long-Term Memory InductionCell, 2009
- The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulationCurrent Opinion in Genetics & Development, 2009
- Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitorsHuman Molecular Genetics, 2009
- Enhancer detection and developmental expression of zebrafish sprouty1, a member of the fgf8 synexpression groupDevelopmental Dynamics, 2008
- Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulationDevelopmental Biology, 2008
- Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase PathwayClinical Cancer Research, 2008
- Oncogene addiction: setting the stage for molecularly targeted cancer therapyGenes & Development, 2007
- Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic optionsHuman Molecular Genetics, 2007
- Cancer drugs to treat birth defectsNature Genetics, 2007
- Generation of FGF reporter transgenic zebrafish and their utility in chemical screensBMC Developmental Biology, 2007